Neural correlates of treatment outcome in major depression.
Lisiecka, Danuta Meisenzahl, Eva Scheuerecker, Johanna Schoepf, Veronica Whitty, Peter Chaney, Aisling Moeller, Hans-Juergen Wiesmann, Martin Frodl, Thomas
Lisiecka, Danuta
Meisenzahl, Eva
Scheuerecker, Johanna
Schoepf, Veronica
Whitty, Peter
Chaney, Aisling
Moeller, Hans-Juergen
Wiesmann, Martin
Frodl, Thomas
An error occurred retrieving the object's statistics
Advisors
Editors
Other Contributors
Departments
Department of Psychiatry, School of Medicine & Trinity College Institute of, Neuroscience, Integrated Neuroimaging, The Adelaide and Meath Hospital, Incorporating the National Children's Hospital (AMiNCH), & St James's Hospital,, Trinity College, Dublin, Ireland.
Date
2012-02-01T10:49:52Z
Date Submitted
Keywords
Other Subjects
Subject Mesh
Adult
Affect/*drug effects
Antidepressive Agents/administration & dosage/*therapeutic use
Biological Markers/analysis
Cerebral Cortex/physiopathology
Cyclohexanols/administration & dosage/*therapeutic use
Depressive Disorder, Major/*drug therapy/physiopathology/psychology
Face
Female
Frontal Lobe/*physiopathology
Humans
Male
Mianserin/administration & dosage/*analogs & derivatives/therapeutic use
Middle Aged
Nerve Net/*drug effects/physiopathology
Psychiatric Status Rating Scales
Treatment Outcome
Young Adult
Affect/*drug effects
Antidepressive Agents/administration & dosage/*therapeutic use
Biological Markers/analysis
Cerebral Cortex/physiopathology
Cyclohexanols/administration & dosage/*therapeutic use
Depressive Disorder, Major/*drug therapy/physiopathology/psychology
Face
Female
Frontal Lobe/*physiopathology
Humans
Male
Mianserin/administration & dosage/*analogs & derivatives/therapeutic use
Middle Aged
Nerve Net/*drug effects/physiopathology
Psychiatric Status Rating Scales
Treatment Outcome
Young Adult
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
There is a need to identify clinically useful biomarkers in major depressive disorder (MDD). In this context the functional connectivity of the orbitofrontal cortex (OFC) to other areas of the affect regulation circuit is of interest. The aim of this study was to identify neural changes during antidepressant treatment and correlates associated with the treatment outcome. In an exploratory analysis it was investigated whether functional connectivity measures moderated a response to mirtazapine and venlafaxine. Twenty-three drug-free patients with MDD were recruited from the Department of Psychiatry and Psychotherapy of the Ludwig-Maximilians University in Munich. The patients were subjected to a 4-wk randomized clinical trial with two common antidepressants, venlafaxine or mirtazapine. Functional connectivity of the OFC, derived from functional magnetic resonance imaging with an emotional face-matching task, was measured before and after the trial. Higher OFC connectivity with the left motor areas and the OFC regions prior to the trial characterized responders (p<0.05, false discovery rate). The treatment non-responders were characterized by higher OFC-cerebellum connectivity. The strength of response was positively correlated with functional coupling between left OFC and the caudate nuclei and thalami. Differences in longitudinal changes were detected between venlafaxine and mirtazapine treatment in the motor areas, cerebellum, cingulate gyrus and angular gyrus. These results indicate that OFC functional connectivity might be useful as a marker for therapy response to mirtazapine and venlafaxine and to reconstruct the differences in their mechanism of action.
Language
eng
ISSN
1469-5111 (Electronic)
1461-1457 (Linking)
1461-1457 (Linking)
eISSN
ISBN
DOI
10.1017/S1461145710001513
PMID
21205435